Aurinia Pharmaceuticals Inc (AUPH)
AUPH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1600620/000160062026000017/0001600620-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AUPH on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001600620 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | ALBERTA, CANADA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $283.1M |
| Net income | $287.2M |
| Operating income | $104.9M |
| Net margin | 101.5% |
| Operating margin | 37.1% |
| Revenue growth | +20.4% |
| Cash | $80.2M |
| Total assets | $751.6M |
| P/E (computed) | 7.2× |
| P/S (computed) | 7.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $45.8M cash; operating cash flow $44.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 133,998,660 (2026-10-29); 131,840,559 a year earlier; 143,608,164 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Edmonton, Canada | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $25.1M, sold $546K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $83.7M | $31.7M | $46.4M | $45.8M | No debt tags | $321.7M | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $83.2M | $37.4M | $52.6M | $179.7M | No debt tags | $311.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $77.7M | $34.4M | $32.6M | $40.7M | No debt tags | $298.3M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $77.1M | $210.8M | $45.7M | $80.2M | No debt tags | $283.1M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $73.5M | $31.6M | $44.4M | $72.9M | No debt tags | $265.8M | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $70.0M | $21.5M | $44.2M | $52.9M | No debt tags | $260.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $62.5M | $23.3M | $1.3M | $66.1M | No debt tags | $247.3M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $59.9M | $1.4M | $30.1M | $83.4M | No debt tags | $235.1M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2021-11-19 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report | 8-K | 2026-10-30 |
| Latest proxy | DEF 14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 615 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.4% |
| 1 month | -3.9% |
| 3 months | +3.6% |
| Year to date | -1.4% |
| 1 year | +3.4% |
| From 52-week high | -15.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMNM | Immunome Inc. | $17.61 | -6.18% | $2.1B |
| BHVN | Biohaven Ltd. Common Shares | $13.80 | -0.14% | $2.1B |
| SDGR | Schrodinger Inc. | $27.36 | -7.35% | $2.1B |
| PVLA | Palvella Therapeutics Inc. | $144.60 | -5.17% | $2.1B |
| SEPN | Septerna Inc. | $41.67 | -2.18% | $2.0B |
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $46.56 | -1.15% | $2.0B |
| VERA | Vera Therapeutics Inc. | $26.97 | -4.02% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier